Harper J W, Auld D S, Riordan J F, Vallee B L
Center for Biochemical and Biophysical Sciences and Medicine, Harvard Medical School, Boston, Massachusetts 02115.
Biochemistry. 1988 Jan 12;27(1):219-26. doi: 10.1021/bi00401a033.
The primary structures of the blood vessel inducing protein human angiogenin and human pancreatic ribonuclease (RNase) are 35% identical. Angiogenin catalyzes the limited cleavage of ribosomal RNA (18 and 28 S), yielding a characteristic pattern of polynucleotide products, but shows no significant activity toward conventional pancreatic RNase substrates [Shapiro, R., Riordan, J. F., & Vallee, B. L. (1986) Biochemistry 25, 3527-3532]. Angiogenin/RNase hybrid enzymes--wherein particular regions of primary structure in RNase are replaced by the corresponding segments of angiogenin--serve to explore the structural features underlying angiogenin's characteristic activities. Herein we show that synthetic angiogenin peptides, Ang(1-21) and Ang(108-123), form noncovalent complexes with inactive fragments of bovine RNase A--RNase(21-124) (i.e., S-protein) and RNase(1-118), respectively--with regeneration of activity toward conventional RNase substrates. Maximal activities for the Ang(1-21)/S-protein complex (Kd = 1.0 microM) are 52%, 45%, and 15% toward cytidine cyclic 2',3'-phosphate, cytidylyl(3'----5')adenosine, and yeast RNA, respectively. In contrast, activities of the RNase(1-118)/Ang(108-123) hybrid (Kd = 25 microM) are 1-2 orders of magnitude lower toward cyclic nucleotides and dinucleoside phosphates. However, substitution of phenylalanine for Leu-115 in Ang(108-123) increases activity up to 100-fold. Both His-13 and His-114 in the angiogenin peptides are required for activity since their substitution by alanine yields inactive complexes. Importantly, the pattern of polynucleotide products formed during cleavage of ribosomal RNA by the Ang(1-21)/S-protein hybrid shows a striking resemblance to that formed by angiogenin, demonstrating that the hybrid retains features of both angiogenin and RNase A.(ABSTRACT TRUNCATED AT 250 WORDS)
血管生成诱导蛋白人血管生成素与人类胰腺核糖核酸酶(RNase)的一级结构有35%的同源性。血管生成素催化核糖体RNA(18S和28S)的有限切割,产生具有特征性的多核苷酸产物模式,但对传统的胰腺RNase底物无显著活性[夏皮罗,R.,里奥丹,J.F.,&瓦利,B.L.(1986年)《生物化学》25卷,3527 - 3532页]。血管生成素/RNase杂合酶——其中RNase一级结构的特定区域被血管生成素的相应片段取代——用于探索血管生成素特征活性背后的结构特征。在此我们表明,合成的血管生成素肽Ang(1 - 21)和Ang(108 - 123)分别与牛RNase A的无活性片段RNase(21 - 124)(即S - 蛋白)和RNase(1 - 118)形成非共价复合物,并恢复对传统RNase底物的活性。Ang(1 - 21)/S - 蛋白复合物(解离常数Kd = 1.0微摩尔)对环胞苷2',3'-磷酸、胞苷酰(3'→5')腺苷和酵母RNA的最大活性分别为52%、45%和15%。相比之下,RNase(1 - 118)/Ang(108 - 123)杂合体(Kd = 25微摩尔)对环核苷酸和二核苷磷酸的活性低1 - 2个数量级。然而,将Ang(108 - 123)中的亮氨酸-115替换为苯丙氨酸会使活性提高100倍。血管生成素肽中的组氨酸-13和组氨酸-114对活性都是必需的,因为用丙氨酸替换它们会产生无活性的复合物。重要的是,Ang(1 - 21)/S - 蛋白杂合体切割核糖体RNA过程中形成的多核苷酸产物模式与血管生成素形成的模式惊人地相似,这表明该杂合体保留了血管生成素和RNase A的特征。(摘要截断于250字)